Trinity Biotech plc (NASDAQ:TRIB) is reporting second quarter financial results on Tuesday 25th August 2020, before market open.
Previous Quarter Performance
Trinity Biotech plc posted income for the first quarter of $ 0.05 per share, from the revenue of $ 21.18 million. The quarterly earnings improved 25.00 percent while revenues declined 3.86 percent compared with the same quarter last year. According to street consensus, revenue of $ 22.50 million was expected for the first quarter The top line results fell short of analysts by $ 1.32 million or 5.87 percent.
Stock Performance
Shares of Trinity Biotech plc traded low $ -0.02 or -1.18 percent on Monday, reaching $ 1.68 with volume of 605.00 thousand shares. Trinity Biotech plc has traded high as $ 1.79 and has cracked $ 1.67 on the downward trend
According to the previous trading day, closing price of $ 1.68, representing a 203.57 % increase from the 52 week low of $ 0.56 and a 48.17 % decrease over the 52 week high of $ 3.28.
The company has a market capital of $ 40.39 million and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
Trinity Biotech plc will be hosting a conference call at 11:00 AM eastern time on 25th August 2020, to discuss its 2Q20 financial results with the investment community. The participants may dial, 1-844-861-5499 Toll Free, (United States) or 1-412-317-6581 Toll Number in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website 78449.choruscall.com/dataconf/productusers/trib/mediaframe/40218/indexr.html
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia.
